{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:33:13Z","timestamp":1791657193182,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Model\u2010informed drug development (MIDD) entails applying quantitative approaches to assist with decision\u2010making during drug development and has been used for dose optimization, to inform clinical trial design, and to support clinical trial waivers. With increasing cost and competitiveness in drug development, the use of tools that improve efficiency, like MIDD, is increasingly crucial. A unique case for the successful application of MIDD approaches from early Phase 1 through postapproval for the upadacitinib development program is described herein. Upadacitinib is an orally administered selective Janus kinase inhibitor, which is approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, axial spondylarthritis, nonradiographic axial spondyloarthritis, ulcerative colitis, and Crohn's disease for adults, in addition to recent approvals for polyarticular juvenile idiopathic arthritis and pediatric patients with psoriatic arthritis. Applications and impact of modeling and simulation approaches for informing key development decisions are presented to highlight the success of using MIDD for the clinical development of upadacitinib. The lessons learned can provide a framework for the clinical development of other drugs.<\/jats:p>","DOI":"10.1111\/cts.70295","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:39:54Z","timestamp":1754437194000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Model\u2010Informed Paradigm in Drug Development\u2014An End\u2010To\u2010End Case Study From Upadacitinib Development"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-8131","authenticated-orcid":false,"given":"Sumit","family":"Bhatnagar","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-4447","authenticated-orcid":false,"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2189","authenticated-orcid":false,"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-3798","authenticated-orcid":false,"given":"Patrick","family":"Marroum","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-1230","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2025","authenticated-orcid":false,"given":"Mohamed\u2010Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1363"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2265"},{"key":"e_1_2_9_4_1","unstructured":"IQVIA Institute for Human Data Science \u201cGlobal Trends in R&D 2024: Activity P. and Enablers \u201d(2024) www.iqviainstitute.org. A.f."},{"key":"e_1_2_9_5_1","unstructured":"AbbVie Inc. \u201cRINVOQ (Upadacitinib Extended\u2010Release Tablets) [US Package Insert] \u201d(2022)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1513"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.918604"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.804"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0605-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1375"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1668"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1543"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.462"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1671"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13146"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","unstructured":"A. V.Ponce\u2010Bobadilla S.Stodtmann D.Eckert W.Zhou W.Liu andM. E.Mohamed \u201cPharmacokinetics and Exposure\u2010Response Analyses of Upadacitinib in Patients With Moderate to Severe Ulcerative Colitis\u2010 Analyses of Induction and Maintenance Clinical Trials \u201d17th Congress of ECCO (European Crohn's and Colitis Organisation)(2022) vol. S1 i355\u2013i357.","DOI":"10.1093\/ecco-jcc\/jjab232.468"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13733"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15803"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13329"},{"key":"e_1_2_9_21_1","unstructured":"Food and Drug Administration & Center for Drug Evaluation and Research \u201cApplication Number 211675Orig1s000. Product Clinical Pharmacology and BioPharmaceutics Review(s) for Upadacitinib Extended Release Tablets \u201d(2019)."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0378-y"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00681-6"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.07.003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3441"},{"key":"e_1_2_9_26_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research & (CBER) \u201cC.f.B.E.a.R. E11A Pediatric Extrapolation: Guidance for Industry \u201d(2024)."}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T17:20:55Z","timestamp":1755969655000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/cts.70295"],"URL":"https:\/\/doi.org\/10.1111\/cts.70295","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70295"}}